arrow
F

Faina Nakhlis

Harvard Medical School
H指数:21
被引数:1,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database

评估通过“Count Me In”倡议数据库中的转移性乳腺癌项目报告的炎性乳腺癌自我诊断的准确性

2025-12-240
PRE
Preliminary Efficacy/Feasibility Study of a Breast Cancer-Related Lymphedema Prospective Screening and Early Intervention Program at the Dana-Farber Brigham Cancer Center

初步疗效/可行性研究:在Dana-Farber Brigham癌症中心开展的一项乳腺癌相关淋巴水肿前瞻性筛查与早期干预计划

2025-10-060
OAAI
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

厄罗替尼、多柔比星和环磷酰胺新辅助治疗HER2阴性炎性乳腺癌:一项II期研究

2025-10-030
OA
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

新辅助HER2靶向方案联合或未联合蒽环类药物用于HER2阳性炎性乳腺癌:一项多中心回顾性研究

2025-08-020
PRE
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

开发一个多机构数据集以验证一种新型炎性乳腺癌诊断评分

2025-03-310
PRE
ASO Visual Abstract: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034)
2025-01-270
PRE
Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034)
2025-01-030
PRE
Generative artificial intelligence as a source of breast cancer information for patients: Proceed with caution

生成式人工智能作为患者乳腺癌信息的来源: 谨慎行事

CANCER
IF5.1
2024-08-303
PRE
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
2024-05-020
PRE
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study
2024-05-020
PRE
Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system
2024-05-020
PRE
Comprehensive clinicogenomic characterization of inflammatory breast cancer
2024-05-020
PRE
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

TBCRC 039: 术前ruxolitinib联合或不联合紫杉醇治疗三阴性炎性乳腺癌的II期研究

2024-01-314
OAAI